The 340B Drug Pricing Program is vital for safety-net healthcare providers, allowing them to enhance access to medications, reduce medication costs for vulnerable populations, and
Oncology medicine spending is rising quickly. Over a five-year period, spending is expected to grow almost 75%. According to recent data, global spending on cancer medicines
Join our host, Lesley Pink, for our monthly podcast, The Strategic Dose, to learn from experts about breaking news, pharmacy and healthcare trends, and more. Listen
According to the FDA, a biosimilar is a biologic that is highly similar to another biologic that has been approved by the FDA. A biosimilar
Federal and state reform has shaped 340B developments this year. These developments could change how hospitals, health centers, and pharmacies manage drug pricing, eligibility, patient access, and cash flow. Below we
340B Leaders Upfront is your exclusive window into the industry leaders that provide products and services to hospitals, community health centers and other 340B providers
Join our host, Lesley Pink, for our monthly podcast, The Strategic Dose, to learn from experts about breaking news, pharmacy and healthcare trends, and more. Listen
New research has found that nearly three-quarters of hospital and pharmacy leaders say the urgency to address community gaps in pharmacy access has increased, and
VytlOne, the nation’s only independent, fully integrated total pharmacy solutions partner, proudly marks its 100th anniversary—a century of innovation, partnership, and impact in healthcare. The
Leading accreditor Accreditation Commission for Health Care (ACHC) announced today it is renewing its strategic partnership with VytlOne, the nation’s only independent, fully integrated total
